A new breast cancer drug has gained approval from the FDA but there is some criticism from others. Avastin is used with chemotherapy in late stage breast cancer patients to stop the growth of tumors. Genentech, the maker of the drug, says it gives patients more time.
Dr. David Schenkein of Genentech says, "It extends the amount of time a woman is alive without her disease progressing from 5.5 months to over 11 months."
But Avastin is controversial and expensive. Critics argue that the drug doesn't improve life but only prolongs it. It costs around $7,000 dollars each month. Genentech says it will establish a cap- offering the drug for free after a patient has spent $55,000.